Search the Newsreel

The Oncology Institute, Inc. (STLN) Income Statement

The article provides the income statement for The Oncology Institute, Inc. (STLN) showing financial data for annual and quarterly periods up to 2025-12-31, with a TTM (trailing twelve months) column. Key financial metrics such as total revenue, gross profit, operating income, and net income …

The Oncology Institute, Inc. $TOI Shares Bought by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership significantly increased its stake in The Oncology Institute, Inc. ($TOI) by 169.3% in the first quarter, now owning 419,423 shares valued at approximately $1.29 million. Other institutional investors like Goldman Sachs and Geode Capital Management also made notable changes to …

Oncology Institute Q2 Earnings Call Highlights

Oncology Institute reported strong Q2 revenue growth, positive adjusted EBITDA, and rebranded as Starling Oncology to reflect its evolution into a national value-based oncology provider. The company expanded its value-based contracts, adding new agreements in Nevada, Oregon, and California, which are expected to significantly …

Insider Ambaw Bellete plans CGON (CGON) stock sale after large prior trades

Ambaw Bellete, an insider at CG Oncology, Inc. (CGON), has filed a Form 144 indicating an intent to sell up to 9,250 shares of common stock on August 7, 2026, through Morgan Stanley Smith Barney LLC. This filing also details several significant common stock …

Royal Bank Of Canada Has Lowered Expectations for CG Oncology (NASDAQ:CGON) Stock Price

Cardiff Oncology Inc (CRDF) Earnings Forecast: Future EPS & Revenue Growth Estimates

Cardiff Oncology Inc (CRDF) has an earnings forecast score of 7.25, ranking 296 out of 387 in the Biotechnology & Medical Research industry. Analysts have set an average price target of $10.00, with a high of $19.00 and a low of $3.50, based on …

Oncology Institute Inc (TOI) Earnings Forecast: Future EPS & Revenue Growth Estimates

Renaissance Technologies LLC Sells 307,595 Shares of Cullinan Therapeutics, Inc. $CGEM

Renaissance Technologies LLC has reduced its stake in Cullinan Therapeutics (NASDAQ:CGEM) by 48.7% during the first quarter, selling 307,595 shares and retaining 324,111 shares valued at $4.6 million. Despite this sale, institutional investors collectively hold 86.31% of the company's stock, and analysts maintain a …

Truist Financial Issues Positive Forecast for CG Oncology (NASDAQ:CGON) Stock Price

Colombier Acquisition Corp II (CLBR) Stock News Today

Kura Oncology, Inc. (KURA) Stock Price, News, Quote & History

This Yahoo Finance page provides comprehensive financial data for Kura Oncology, Inc. (KURA), including its current stock price, historical performance, key statistics, earnings trends, and analyst ratings. It also offers an overview of the company's biopharmaceutical operations, focusing on its cancer treatment drug development.

BofA Adjusts Price Target on CG Oncology to $88 From $87

BofA Securities has raised its price target for CG Oncology (CGON) shares to $88 from $87, while maintaining a Buy rating. This adjustment follows a previous price target revision by RBC, which lowered its target to $79 from $81. The article highlights recent news …

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kura Oncology, Inc. announced that its Compensation Committee granted inducement awards consisting of nonstatutory stock options to purchase 104,500 shares of common stock to six new employees. These grants were made on August 3, 2026, under the Company’s 2023 Inducement Option Plan, as amended, …

Six New Employees Receive Kura Oncology Options at $9.19

Kura Oncology (Nasdaq: KURA) has granted inducement awards of nonstatutory stock options to six new employees, totaling 104,500 shares. The options have an exercise price of $9.19 per share, matching the closing price on August 3, 2026, and will vest over four years. These …

Colony Bankcorp Inc (CBAN) Stock News Today

How Investors Are Reacting To CG Oncology (CGON) Wider Quarterly Loss Amid Promising Phase 3 Bladder Cancer Data

CG Oncology recently reported a wider net loss of US$79.06 million in Q2 2026, while generating US$1.16 million in revenue. Despite the financial setback, the company is advancing its lead drug, cretostimogene grenadenorepvec, for non-muscle invasive bladder cancer, with promising Phase 3 data published …

Champions Oncology Inc (CSBR) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Champions Oncology Inc (CSBR), noting that no earnings forecast score is currently available, but the industry average is 8.10. Analysts have set a consistent price target of $12.00, with an upside potential of over 109%. The report …

Cullinan Therapeutics (NASDAQ:CGEM) Issues Quarterly Earnings Results

Racura Oncology (ASX:RAC) in Focus as Investors Track Precision Medicine Progress

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Cullinan Therapeutics announced its second-quarter 2026 financial results and provided a corporate update, highlighting progress in its immunology and oncology pipeline. The company reported promising clinical data for CLN-978 and velinotamig in autoimmune diseases, with Phase 2 studies anticipated to begin in early 2027. …

CG Oncology, Inc. Stock 12‑Month Price Target Raised to $91.15, Implies 26% Upside

CG Oncology, Inc.'s average 12-month stock price target has increased from $90.69 to $91.15, based on estimates from 13 analysts, suggesting a 26% potential upside from its August 5 closing price. The consensus rating for CGON remains a "Buy" among 15 analysts, with 14 …

(CLBR) Volatility Zones as Tactical Triggers

Colombier Acquisition Corp. Ii Class A (NASDAQ: CLBR) is showing stable neutral readings in shorter horizons, potentially indicating an easing of a long-term weak bias. The article details a mid-channel oscillation pattern and highlights an exceptional 67.7:1 risk-reward setup targeting a 20.6% gain against …

ALX Oncology Holdings Inc 2Q 2026: Net loss $17.97M, Diluted EPS $(0.13) — 10-Q Summary

ALX Oncology Holdings Inc. reported a reduced net loss of $17.97M in Q2 2026, down from $25.95M in Q2 2025, with diluted EPS improving to $(0.13) from $(0.49). This improvement is attributed to lower operating expenses resulting from streamlined clinical programs. The company highlighted …

Form 8K Oncology Institute Inc For: 6 August By Investing.com

The article reports on an 8K filing by Oncology Institute Inc. for August 6. It includes a stock market publication timestamp and references the company's stock symbol STLN. The content also features various market data, trending stocks, and related news headlines.

Understanding the Setup: (CBAN) and Scalable Risk

This article provides an analysis of Colony Bankcorp Inc. (NASDAQ: CBAN), highlighting strong sentiment, a mid-channel oscillation pattern, and an exceptional 23.0:1 risk-reward setup. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, along …

Insider (NASDAQ: CGON) files to sell 75,000 shares after recent stock sales

Ambaw Bellete, an insider at CG Oncology, Inc. (NASDAQ: CGON), has filed to sell 75,000 shares of common stock through Morgan Stanley's Executive Financial Services program, linked to a stock option exercise on August 6, 2026. This proposed sale has an aggregate market value …

CG Oncology earnings up next amid bladder cancer therapy push By Investing.com

CG Oncology Inc. is set to report second-quarter earnings, with analysts expecting a narrower loss as the company progresses towards a regulatory filing for its bladder cancer treatment. The biotech aims to complete its Biologics License Application by Q4 2026, positioning it for potential …

Aktis Oncology (NASDAQ:AKTS) Receives Average Recommendation of "Moderate Buy" from Brokerages

Aktis Oncology (NASDAQ:AKTS) has received a consensus "Moderate Buy" rating from eight analysts, with an average 12-month price target of $34.60. The company reported quarterly revenue of $3.23 million, surpassing estimates, though its loss per share slightly missed expectations. Insider trading activity included a …

Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history

This article provides a detailed overview of Cullinan Therapeutics, Inc. (CGEM), a clinical-stage biopharmaceutical company focused on autoimmune diseases and cancer. It includes current stock price, historical data, financial metrics, analyst ratings, and a company profile highlighting its drug development pipeline. The company's stock …

CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates

CG Oncology, Inc. (CGON) reported a Q2 loss of $0.9 per share, missing the Zacks Consensus Estimate of a $0.7 loss, and posted revenues of $1.16 million, which fell short of estimates by 59.02%. Despite the earnings miss, the company's shares have risen 74.4% …

COLONY BANKCORP INC Q2 2026: Revenue $45.78M, Net income $10.86M, EPS $0.51— 10-Q Summary

COLONY BANKCORP INC (CBAN) reported strong second-quarter 2026 results, with revenue reaching $45.78 million and net income climbing to $10.86 million, leading to a diluted EPS of $0.51. The positive performance was attributed to increased loan interest income and an expanded net interest margin. …

Earnings Flash (CGON) CG Oncology, Inc. Reports Q2 Revenue $1.2M

Pyxis Oncology (PYXS) Projected to Release Quarterly Earnings on Thursday

Pyxis Oncology (NASDAQ:PYXS) is scheduled to release its Q2 2026 earnings before market open on Thursday, August 13th. Analysts anticipate a loss of $0.34 per share and revenue of $33,000, continuing a trend of projected annual losses of around $1 per share. Despite mixed …

CG Oncology (NASDAQ: CGON) posts $139.3M half-year loss with $1,028.3M cash

ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update

ALX Oncology (Nasdaq: ALXO) announced its financial results for the second quarter ended June 30, 2026, highlighting progress in its clinical programs, including the ASPEN-09-Breast trial for evorpacept and the Phase 1 trial for ALX2004. The company reported a strengthened balance sheet, with cash …

CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates

CG Oncology Inc. reported its second-quarter 2026 financial results, highlighting significant progress in clinical, regulatory, manufacturing, and commercial-readiness initiatives. Key milestones include anticipated Phase 3 topline data for PIVOT-006, expected BLA completion for HR BCG-unresponsive NMIBC in Q4 2026, and the publication of BOND-003 …